Wyeth earnings
This article was originally published in The Tan Sheet
Executive Summary
Worldwide consumer healthcare sales increased 5% to $616 mil. in the first quarter on the strength of the Robitussin, Advil and Caltrate brands, Wyeth reports in an April 20 earnings call. The firm's U.S. consumer unit "continues to track the marketplace," while the international business grew double-digits, CFO Ken Martin said. Consumer net revenue was up 3% without the favorable impact of currency. Total sales grew 14% to $4.6 bil. during the quarter, with net earnings up 43% to $1.1 bil. The firm anticipates full-year EPS at the upper end of its $2.70-$2.80 guidance...